Latest news with #GAD
Business Wire
13 hours ago
- Business
- Business Wire
Cybin Announces Additional U.S. Patent Supporting its CYB004 Program in Phase 2 Development for Generalized Anxiety Disorder
TORONTO--(BUSINESS WIRE)-- Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (' Cybin ' or the ' Company '), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, today announced that the United States Patent and Trademark Office has granted U.S. patent 12,318,477 in support of its CYB004 deuterated DMT program in development for the treatment of generalized anxiety disorder ('GAD'). The patent, which is expected to provide exclusivity until 2040, includes claims to novel formulations of DMT and deuterated isotopologues for intramuscular ('IM') injection, including CYB004. 'Patents are extremely valuable assets, and protection for our lead product candidates is a top priority for us,' said Doug Drysdale, Chief Executive Officer of Cybin. 'We believe that our CYB004 program has the potential to deliver short-duration, rapid-acting treatment for anxiety disorders and offer more patient-friendly dosing methods such as IM administration. The issuance of this additional patent in support of CYB004 adds further validation of this important program. Dosing is currently underway in our Phase 2 study evaluating CYB004 in generalized anxiety disorder, and we expect the study to complete around mid-year. I'm proud that Cybin has amassed one of the strongest IP portfolios in the sector with more than 90 granted patents and over 230 pending applications.' About Cybin Cybin is a late-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options to address the large unmet need for people who suffer from mental health conditions. With industry leading proof-of-concept data, Cybin is working to change the mental health treatment landscape through the introduction of intermittent treatments that provide long lasting results. The Company is currently developing CYB003, a proprietary deuterated psilocin program, in Phase 3 development for the adjunctive treatment of major depressive disorder and CYB004, a proprietary deuterated N, N-dimethyltryptamine program in a Phase 2 study for generalized anxiety disorder. The company also has a research pipeline of investigational, 5-HT-receptor focused compounds. Founded in 2019, Cybin is operational in Canada, the United States, the United Kingdom, the Netherlands and Ireland. For Company updates and to learn more about Cybin, visit or follow the team on X, LinkedIn, YouTube and Instagram. Cautionary Notes and Forward-Looking Statements Certain statements in this news release relating to the Company are forward-looking statements and are prospective in nature. Forward-looking statements are not based on historical facts, but rather on current expectations and projections about future events and are therefore subject to risks and uncertainties which could cause actual results to differ materially from the future results expressed or implied by the forward-looking statements. These statements generally can be identified by the use of forward-looking words such as 'may', 'should', 'could', 'intend', 'estimate', 'plan', 'anticipate', 'expect', 'believe' or 'continue', or the negative thereof or similar variations. Forward-looking statements in this news release include statements regarding the Company's expectations respecting the patent exclusivity period; plans to complete the Phase 2 GAD study around mid-year 2025; and the Company's plans to engineer proprietary drug discovery platforms, innovative drug delivery systems, novel formulation approaches and treatment regimens for mental health disorders. These forward-looking statements are based on reasonable assumptions and estimates of management of the Company at the time such statements were made. Actual future results may differ materially as forward-looking statements involve known and unknown risks, uncertainties, and other factors which may cause the actual results, performance, or achievements of the Company to materially differ from any future results, performance, or achievements expressed or implied by such forward-looking statements. Such factors, among other things, include: implications of the spread of a pandemic on the Company's operations; fluctuations in general macroeconomic conditions; fluctuations in securities markets; expectations regarding the size of the psychedelics market; the ability of the Company to successfully achieve its business objectives; plans for growth; political, social and environmental uncertainties; employee relations; the presence of laws and regulations that may impose restrictions in the markets where the Company operates; and the risk factors set out in each of the Company's management's discussion and analysis for the three and nine month periods ended December 31, 2024 and the Company's annual information form for the year ended March 31, 2024, which are available under the Company's profile on SEDAR+ and with the U.S. Securities and Exchange Commission on EDGAR at Although the forward-looking statements contained in this news release are based upon what management of the Company believes, or believed at the time, to be reasonable assumptions, the Company cannot assure shareholders that actual results will be consistent with such forward-looking statements, as there may be other factors that cause results not to be as anticipated, estimated or intended. Readers should not place undue reliance on the forward-looking statements and information contained in this news release. The Company assumes no obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change, except as required by law. Cybin makes no medical, treatment or health benefit claims about Cybin's proposed products. The U.S. Food and Drug Administration, Health Canada or other similar regulatory authorities have not evaluated claims regarding psilocin, psychedelic tryptamine, tryptamine derivatives or other psychedelic compounds. The efficacy of such products has not been confirmed by approved research. There is no assurance that the use of psilocin, psychedelic tryptamine, tryptamine derivatives or other psychedelic compounds can diagnose, treat, cure or prevent any disease or condition. Rigorous scientific research and clinical trials are needed. If Cybin cannot obtain the approvals or research necessary to commercialize its business, it may have a material adverse effect on Cybin's performance and operations. Neither the Cboe Canada nor the NYSE American LLC stock exchange have approved or disapproved the contents of this news release and are not responsible for the adequacy and accuracy of the contents herein.
Yahoo
13 hours ago
- Business
- Yahoo
Cybin Announces Additional U.S. Patent Supporting its CYB004 Program in Phase 2 Development for Generalized Anxiety Disorder
- Newly issued patent includes claims to novel formulations of N,N-dimethyltryptamine ("DMT") and deuterated isotopologues for intramuscular injection, including CYB004, with expected exclusivity until 2040 - - Cybin's growing intellectual property portfolio comprises more than 90 granted patents and over 230 pending applications - TORONTO, June 03, 2025--(BUSINESS WIRE)--Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) ("Cybin" or the "Company"), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, today announced that the United States Patent and Trademark Office has granted U.S. patent 12,318,477 in support of its CYB004 deuterated DMT program in development for the treatment of generalized anxiety disorder ("GAD"). The patent, which is expected to provide exclusivity until 2040, includes claims to novel formulations of DMT and deuterated isotopologues for intramuscular ("IM") injection, including CYB004. "Patents are extremely valuable assets, and protection for our lead product candidates is a top priority for us," said Doug Drysdale, Chief Executive Officer of Cybin. "We believe that our CYB004 program has the potential to deliver short-duration, rapid-acting treatment for anxiety disorders and offer more patient-friendly dosing methods such as IM administration. The issuance of this additional patent in support of CYB004 adds further validation of this important program. Dosing is currently underway in our Phase 2 study evaluating CYB004 in generalized anxiety disorder, and we expect the study to complete around mid-year. I'm proud that Cybin has amassed one of the strongest IP portfolios in the sector with more than 90 granted patents and over 230 pending applications." About Cybin Cybin is a late-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options to address the large unmet need for people who suffer from mental health conditions. With industry leading proof-of-concept data, Cybin is working to change the mental health treatment landscape through the introduction of intermittent treatments that provide long lasting results. The Company is currently developing CYB003, a proprietary deuterated psilocin program, in Phase 3 development for the adjunctive treatment of major depressive disorder and CYB004, a proprietary deuterated N, N-dimethyltryptamine program in a Phase 2 study for generalized anxiety disorder. The company also has a research pipeline of investigational, 5-HT-receptor focused compounds. Founded in 2019, Cybin is operational in Canada, the United States, the United Kingdom, the Netherlands and Ireland. For Company updates and to learn more about Cybin, visit or follow the team on X, LinkedIn, YouTube and Instagram. Cautionary Notes and Forward-Looking Statements Certain statements in this news release relating to the Company are forward-looking statements and are prospective in nature. Forward-looking statements are not based on historical facts, but rather on current expectations and projections about future events and are therefore subject to risks and uncertainties which could cause actual results to differ materially from the future results expressed or implied by the forward-looking statements. These statements generally can be identified by the use of forward-looking words such as "may", "should", "could", "intend", "estimate", "plan", "anticipate", "expect", "believe" or "continue", or the negative thereof or similar variations. Forward-looking statements in this news release include statements regarding the Company's expectations respecting the patent exclusivity period; plans to complete the Phase 2 GAD study around mid-year 2025; and the Company's plans to engineer proprietary drug discovery platforms, innovative drug delivery systems, novel formulation approaches and treatment regimens for mental health disorders. These forward-looking statements are based on reasonable assumptions and estimates of management of the Company at the time such statements were made. Actual future results may differ materially as forward-looking statements involve known and unknown risks, uncertainties, and other factors which may cause the actual results, performance, or achievements of the Company to materially differ from any future results, performance, or achievements expressed or implied by such forward-looking statements. Such factors, among other things, include: implications of the spread of a pandemic on the Company's operations; fluctuations in general macroeconomic conditions; fluctuations in securities markets; expectations regarding the size of the psychedelics market; the ability of the Company to successfully achieve its business objectives; plans for growth; political, social and environmental uncertainties; employee relations; the presence of laws and regulations that may impose restrictions in the markets where the Company operates; and the risk factors set out in each of the Company's management's discussion and analysis for the three and nine month periods ended December 31, 2024 and the Company's annual information form for the year ended March 31, 2024, which are available under the Company's profile on SEDAR+ and with the U.S. Securities and Exchange Commission on EDGAR at Although the forward-looking statements contained in this news release are based upon what management of the Company believes, or believed at the time, to be reasonable assumptions, the Company cannot assure shareholders that actual results will be consistent with such forward-looking statements, as there may be other factors that cause results not to be as anticipated, estimated or intended. Readers should not place undue reliance on the forward-looking statements and information contained in this news release. The Company assumes no obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change, except as required by law. Cybin makes no medical, treatment or health benefit claims about Cybin's proposed products. The U.S. Food and Drug Administration, Health Canada or other similar regulatory authorities have not evaluated claims regarding psilocin, psychedelic tryptamine, tryptamine derivatives or other psychedelic compounds. The efficacy of such products has not been confirmed by approved research. There is no assurance that the use of psilocin, psychedelic tryptamine, tryptamine derivatives or other psychedelic compounds can diagnose, treat, cure or prevent any disease or condition. Rigorous scientific research and clinical trials are needed. If Cybin cannot obtain the approvals or research necessary to commercialize its business, it may have a material adverse effect on Cybin's performance and operations. Neither the Cboe Canada nor the NYSE American LLC stock exchange have approved or disapproved the contents of this news release and are not responsible for the adequacy and accuracy of the contents herein. View source version on Contacts Investor & Media Contact: Gabriel FahelChief Legal OfficerCybin Inc.1-866-292-4601irteam@ – or – media@ Sign in to access your portfolio
&w=3840&q=100)
Business Standard
14 hours ago
- Business
- Business Standard
Maharashtra allows disciplinary notices via email, WhatsApp in digital push
The Maharashtra government, through an official notification, directed that in cases of indiscipline by any government employee or officer, notices for action and other necessary documents should be served to the concerned employee via email and WhatsApp. The government permitted disciplinary notices to be sent via email and WhatsApp, alongside the existing registered post method. The move aimed to streamline administrative communication and accelerate official procedures, particularly in cases of misconduct or disciplinary action against government employees or officers. The General Administration Department (GAD) issued the official circular yesterday, stating that digital platforms can now be used to send notices, related documentation, and other official communication in cases of government disciplinary proceedings. The circular stated, "In case of any official indiscipline by any government employee or officer, notice for action and other necessary documentation can be sent to the concerned employee via email and WhatsApp." However, the traditional practice of serving notices through registered post has not been discontinued. The circular added that notices will also be served via registered post, making it a dual-mode delivery system to ensure the communication reaches the recipient effectively. This decision came in the backdrop of the government's larger vision of administrative reform and development under "Developed Maharashtra - 2047," a part of India's broader vision of becoming a developed nation by 2047. As part of this mission, the Maharashtra government launched an extensive 150-day programme from May 6 to October 2, 2025, aimed at finalising a comprehensive Vision Document for Maharashtra's growth. The initiative aligned with national goals, such as a $5 trillion economy by 2025-26, while also setting state-specific targets for infrastructure, agriculture, industry, education, health, and urban development. To prepare this Vision Document, the state appointed sectoral groups, coordinators, and external experts across 16 departments, including agriculture, education, health, environment, and urban planning. The government also planned state-wide surveys to gather citizens' feedback and aspirations for Maharashtra's future. The Vision Document will be finalised by October 2, 2025, and will lay down short-term, medium-term, and long-term developmental goals up to 2047, marking India's centenary of independence. Meanwhile, the Planning Department of Maharashtra, led by Chief Minister Devendra Fadnavis, issued a Government Resolution (GR) asking all state departments to prepare a vision document titled "Developed Maharashtra 2047." This will be on the lines of the Union Government's scheme of Viksit Bharat 2047 as outlined by Prime Minister Narendra Modi. Chief Minister Devendra Fadnavis has set 150 days from May 6 to October 2 to prepare the document, which will primarily focus on a phase-wise vision. The first phase includes a long-term vision or plan for developing Maharashtra by 2047. The midterm phase includes vision or plans to prepare a plan for Maharashtra 2035, when the state will complete its 75 years of its foundation. The third phase includes a short-term plan to prepare a vision document for October 2029, when the present government will complete its five-year term.
Time of India
5 days ago
- Politics
- Time of India
Kerala government sets up screening committee for election commission approvals during Nilambur byelection
1 2 T'puram: The state govt has constituted a high-level screening committee to expedite the scrutiny and clearance of govt proposals requiring prior approval from the Election Commission (EC) in view of the enforcement of the model code of conduct (MCC) ahead of the upcoming byelection in the Nilambur assembly constituency. An official order issued on Wednesday said the committee aims to streamline the approval process and ensure timely disposal of all proposals falling under the MCC purview. The move is part of efforts to maintain administrative continuity without violating election protocols. The committee, chaired by the chief secretary, will also include the general administration department (GAD) secretary as convener. The third member will be the additional chief secretary, principal secretary or secretary of the department concerned, depending on the subject matter of the proposal under consideration. As per the order, the committee is mandated to meet every Monday at 11am or as and when necessary to examine individual proposals. Only after detailed vetting in line with the MCC manual and compendium of instructions will proposals be forwarded to the chief electoral officer (CEO) of Kerala, who will seek final clearance from EC. Departments have been directed to submit cases to the office of the GAD secretary (convener) well in advance, with a comprehensive note justifying the urgency of the proposal and explaining why it cannot wait until the completion of the election process. Notably, no department will be allowed to send proposals directly to the CEO's office or the EC without the screening committee's recommendation. The order underlines the importance of institutional coordination and adherence to electoral protocols during the MCC period, reinforcing the govt's commitment to a fair and transparent election process.
The Hindu
6 days ago
- Politics
- The Hindu
Governor Abdul Nazeer, Chief Secretary Vijayanand pay tributes to NTR on his birth anniversary
Rich tributes were paid to noted actor and former Chief Minister Nandamuri Taraka Rama Rao (NTR) on May 28 (Wednesday) on the occasion of his birth anniversary. The Government of Andhra Pradesh decided to officially observe the day as a State-wide function. In his message on X, Andhra Pradesh Governor S. Abdul Nazeer said NTR was in the forefront in women empowerment and in propagating the spirit of Telugu pride at the national and international levels. At the Secretariat, Chief Secretary K. Vijayanand paid floral tributes at NTR's portrait. Senior officials, including Special Chief Secretary (Finance) S.S. Rawat, Principal Secretary (GAD) Mukesh Kumar Meena, Principal Secretary to the Chief Minister M. Ravi Chandra, and Protocol Additional Director Mohan Rao, paid tributes to the late leader. Speaking on the occasion, Mr. Vijayanand said NTR was not just a silver screen icon but also a visionary leader who had introduced several pioneering welfare schemes for the poor, such as ₹2-a-kg rice and housing for all. He recalled NTR's emphasis on decentralised, people-centric governance, and his contribution to uplifting the Telugu pride on national and international platforms. At the Legislative Assembly, Secretary General Suryadevara Prasanna Kumar and Deputy Secretary Raj Kumar paid rich tributes to NTR. They highlighted his relentless service towards ensuring social justice.
